Type 2 Diabetes: Cardiovascular Outcomes with Metformin and Incretin Combination Therapy Compared to Metformin and Sulfonylureas

Author

Brendan K. Lucas, University of the PacificFollow

Date of Award

4-1-2019

Document Type

Capstone

Degree Name

Master of Physician Assistant Studies

Department

Physician Assistant Education

First Advisor

Mark Christiansen

Abstract

Type 2 diabetes is a disease plaguing the American population, bringing along with it a number of complications. With millions of dollars spent annually to care for diabetic patients and the complications of diabetes, much remains to be known regarding newer medications and the effects of those complications. Two sodium glucose co-transporter 2 inhibitors, canagliflozin and empagliflozin, and one glucagon-like peptide-1 receptor agonist, liraglutide, have proven cardiovascular benefit; however, their use in combination with metformin has not been well studied when compared to metformin and sulfonylurea therapy. While there are studies underway evaluating such outcomes, a critical review of current literature has revealed a lack of research to aid in the decision-making process of type 2 diabetes treatment.

Recommended Citation

Lucas, Brendan K., "Type 2 Diabetes: Cardiovascular Outcomes with Metformin and Incretin Combination Therapy Compared to Metformin and Sulfonylureas" (2019). Physician Assistant Capstones. 30.
https://scholarlycommons.pacific.edu/pa-capstones/30